NCT00503113View on ClinicalTrials.gov

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

PHASE4CompletedINTERVENTIONAL
Enrollment

801

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Post-Menopausal Osteoporosis
Interventions
DRUG

ibandronate [Bonviva/Boniva]

3mg intravenous (iv) injection every 3 months

DRUG

ibandronate [Bonviva/Boniva]

3mg intravenous (iv) infusion every 3 months

DRUG

Alendronate

70mg per oral (po) weekly

Trial Locations (44)

2000

Santa Fe

2196

Johannesburg

3010

Bern

3630

Durban

4055

Basel

6001

Port Elizabeth

7130

Somerset West

7500

Parow

8091

Zurich

11000

Mexico City

16635

Duncansville

20817

Bethesda

23502

Norfolk

28557

Morehead City

30501

Gainesville

33401

West Palm Beach

35294

Birmingham

44629

Guadalajara

45224

Cincinnati

52170

San Jerónimo

58103

Fargo

58501

Bismarck

64460

Monterrey

66604

Topeka

68131

Omaha

80227

Lakewood

85000

Obregón

87106

Albuquerque

92505

Riverside

B1878DVB

Buenos Aires

C1012-CFed

Buenos Aires

C1117ABH

Buenos Aires

C1128AAF

Buenos Aires

C1405BCH

Buenos Aires

C1425 AWC

Buenos Aires

C1425AGC

Buenos Aires

X5000BNB

Córdoba

71625-009

Brasília

80030-110

Curitiba

74110-120

Goiânia

90610-000

Porto Alegre

22271-100

Rio de Janeiro

04266-010

São Paulo

29055-450

Vitória

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00503113 - A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. | Biotech Hunter | Biotech Hunter